Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Solvang, CA
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Solvang, CA
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Valencia, CA
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Valencia, CA
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Aurora, CO
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Aurora, CO
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Fort Lauderdale, FL
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Gainesville, FL
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Gainesville, FL
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
New Port Richey, FL
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
New Port Richey, FL
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Atlanta, GA
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Macon, GA
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Macon, GA
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Marietta, GA
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Marietta, GA
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Alton, IL
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Alton, IL
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Chicago, IL
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Skokie, IL
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Skokie, IL
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Elkhart, IN
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Elkhart, IN
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Mishawaka, IN
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Mishawaka, IN
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
South Bend, IN
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
South Bend, IN
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Westville, IN
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Westville, IN
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Lexington, KY
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Lexington, KY
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Lansing, MI
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Lansing, MI
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Minneapolis, MN
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Southaven, MS
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Southaven, MS
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Grand Island, NE
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Grand Island, NE
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Kearney, NE
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Kearney, NE
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Henderson, NV
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Henderson, NV
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
New York, NY
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Charlotte, NC
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Bismarck, ND
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Bismarck, ND
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Oklahoma City, OK
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Portland, OR
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
West Reading, PA
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
West Reading, PA
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Bartlett, TN
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Bartlett, TN
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Germantown, TN
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Germantown, TN
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Memphis, TN
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Memphis, TN
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Niles, TN
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Niles, TN
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Oxford, TN
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Oxford, TN
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Lubbock, TX
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Lubbock, TX
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Temple, TX
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Temple, TX
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Salt Lake City, UT
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Fitzroy,
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Fitzroy,
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Saint Joseph, MI
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Saint Louis, MO
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham, Comprehensive Cancer Center
mi
from
Birmingham, AL
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham, Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
TGEN Clinical Research Service at Scottsdale Healthcare
mi
from
Scottsdale, AZ
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
TGEN Clinical Research Service at Scottsdale Healthcare
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Burbank, CA
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Burbank, CA
Click here to add this to my saved trials
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
UCLA
mi
from
Los Angeles, CA
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Stanford Cancer Center
mi
from
Stanford, CA
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Stanford Cancer Center
mi
from
Stanford, CA
Click here to add this to my saved trials
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
University of Colorado Cancer Center
mi
from
Aurora, CO
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Yale University School of Medicine
mi
from
New Haven, CT
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Washington Cancer Institute
mi
from
Washington,
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Washington Cancer Institute
mi
from
Washington,
Click here to add this to my saved trials
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffet Cancer Center and Research Institute
mi
from
Tampa, FL
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffet Cancer Center and Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials